Selumetinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Selumetinib. Educational only — not medical advice.
Labeled uses
KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) [see Dosage and Administration (2) ].
Source: FDA labeling via NIH DailyMed (set 7d042c61…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.